TITLE

COMMENTARY: Review: Ribavirin is not better than placebo in chronic hepatitis C infection

AUTHOR(S)
Chen, Wendong; Krahn, Murray
PUB. DATE
September 2006
SOURCE
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p47
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents comments on studies examining whether ribavirin is better than placebo in chronic hepatitis C infection. It was seen that ribavirin monotherapy was not associated with significant benefit in terms of sustained viral response. It was not related to liver-related morbidity, or all-cause mortality also. Review of the studies showed that approximately 19% of patients treated with ribavirin might develop anemia. However, withdrawals may be experienced due to adverse effects.
ACCESSION #
22493499

 

Related Articles

  • Review: Ribavirin is not better than placebo in chronic hepatitis C infection.  // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p47 

    The article focuses on studies which examine whether ribavirin monotherapy is more effective than placebo in patients with chronic hepatitis C infection, or whether no intervention is required. Assessment of individual studies was based on randomization, allocation concealment, and blinding. It...

  • A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure. Snoeck, E.; Chanu, P.; Lavielle, M.; Jacqmin, P.; Jonsson, E. N.; Jorga, K.; Goggin, T.; Grippo, J.; Jumbe, N. L.; Frey, N. // Clinical Pharmacology & Therapeutics;Jun2010, Vol. 87 Issue 6, p706 

    We propose a model that characterizes and links the complexity and diversity of clinically observed hepatitis C viral kinetics to sustained virologic response (SVR)—the primary clinical end point of hepatitis C treatment, defined as an undetectable viral load at 24 weeks after completion...

  • Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Oze, Tsugiko; Hiramatsu, Naoki; Kurashige, Nao; Tsuda, Natsuko; Yakushijin, Takayuki; Kanto, Tatsuya; Takehara, Tetsuo; Kasahara, Akinori; Kato, Michio; Yoshihara, Harumasa; Katayama, Kazuhiro; Kubota, Shinji; Hijioka, Taizo; Ishibashi, Kazunobu; Oshita, Masahide; Hagiwara, Hideki; Haruna, Yoshimichi; Mita, Eiji; Tamura, Shinji; Hayashi, Norio // Journal of Gastroenterology;Sep2006, Vol. 41 Issue 9, p862 

    The aim of this study was to examine the factors correlated with the progression of ribavirin-induced hemolytic anemia in patients with chronic hepatitis C treated by interferon and ribavirin combination therapy. This study was conducted on 505 patients by the Osaka Liver Disease Study Group. A...

  • Evidence of Recombination in Intrapatient Populations of Hepatitis C Virus. Sentandreu, Vicente; Jiménez-Hernández, Nuria; Torres-Puente, Manuela; Bracho, María Alma; Valero, Ana; Gosalbes, María José; Ortega, Enrique; Moya, Andrés; González-Candelas, Fernando // PLoS ONE;2008, Vol. 3 Issue 9, p1 

    Hepatitis C virus (HCV) is a major cause of liver disease worldwide and a potential cause of substantial morbidity and mortality in the future. HCV is characterized by a high level of genetic heterogeneity. Although homologous recombination has been demonstrated in many members of the family...

  • Sustained Virological Response to Interferon Plus Ribavirin Reduces Non–Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus. Berenguer, Juan; Rodríguez, Elena; Miralles, Pilar; Von Wichmann, Miguel A.; López-Aldeguer, José; Mallolas, Josep; Galindo, María J.; Van Den Eynde, Eva; Téllez, María J.; Quereda, Carmen; Jou, Antoni; Sanz, José; Barros, Carlos; Santos, Ignacio; Pulido, Federico; Guardiola, Josep M.; Ortega, Enrique; Rubio, Rafael; Jusdado, Juan J.; Montes, María L. // Clinical Infectious Diseases;Sep2012, Vol. 55 Issue 5, p728 

    We observed that eradication of hepatitis C virus in patients coinfected with human immunodeficiency virus (HIV) was associated not only with a reduction in liver-related complications and mortality but also with a reduction in the progression of HIV infection and mortality not related to liver...

  • Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. Macías, Juan; Del Valle, José; Rivero, Antonio; Mira, José A.; Camacho, Ángela; Merchante, Nicolás; Pérez-Camacho, Inés; Neukam, Karin; Rivero-Juárez, Antonio; Mata, Rosario; Torre-Cisneros, Julián; Pineda, Juan A. // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2204 

    Objectives: To evaluate the changes in liver stiffness measurement (LSM) in patients infected by hepatitis C virus (HCV) under pegylated interferon (Peg-IFN) plus ribavirin therapy.

  • Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection. Erqou, Sebhat; Mohanty, Arpan; Kasi, Pashtoon Murtaza; Butt, Adeel A. // ISRN Otolaryngology;2014, p1 

    Background. Understanding the predictors of mortality in individuals with human immunodeficiency virus and hepatitis C virus (HIV/HCV) coinfection can be useful in management of these patients. Methods. We used the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) for these...

  • Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. Kobayashi, Tomoe; Hige, Shuhei; Terashita, Katsumi; Nakai, Masato; Horimoto, Hiromasa; Sho, Takuya; Nakanishi, Mitsuru; Ogawa, Koji; Chuma, Makoto; Sakamoto, Naoya; Asaka, Masahiro // Journal of Gastroenterology;Nov2012, Vol. 47 Issue 11, p1228 

    Background: An inosine triphosphatase ( ITPA) single-nucleotide polymorphism (SNP) is associated with anemia induced by pegylated interferon and ribavirin (RBV) combination therapy in patients with chronic hepatitis C (CHC). However, there are very few reports on the hematological effects of RBV...

  • Treatment of chronic hepatitis C. Davis, Gary L // BMJ: British Medical Journal (International Edition);11/17/2001, Vol. 323 Issue 7322, p1141 

    Editorial. Focuses on treatment of chronic infection with hepatitis C virus. Reduction in the number of new hepatitis C infections as a result of improved blood screening and changes in injected drug use; Risk of death from chronic infections which lead to chronic liver disease; Initial...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics